BIOMARKER:

RAS mutation

RAS mutation RAS mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	RAS mutation RAS mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A2 - Guideline	cabozantinib capsule Sensitive: A2 - Guideline
RAS mutation RAS mutation	Acute Myelogenous Leukemia AML	RAS mutation RAS mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: C2 – Inclusion Criteria	venetoclax Sensitive: C2 – Inclusion Criteria
RAS mutation RAS mutation	Multiple Myeloma Multiple Myeloma	RAS mutation RAS mutation	Multiple Myeloma Multiple Myeloma	selinexor Sensitive: C3 – Early Trials	selinexor Sensitive: C3 – Early Trials
RAS mutation RAS mutation	Colorectal Cancer CRC	RAS mutation RAS mutation	Colorectal Cancer CRC	sorafenib Sensitive: C3 – Early Trials	sorafenib Sensitive: C3 – Early Trials
RAS mutation RAS mutation	Colorectal Cancer CRC	RAS mutation RAS mutation	Colorectal Cancer CRC	EGFR inhibitor Sensitive: C3 – Early Trials	EGFR inhibitor Sensitive: C3 – Early Trials
RAS mutation RAS mutation	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	RAS mutation RAS mutation	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	atezolizumab + cobimetinib Sensitive: C3 – Early Trials	atezolizumab + cobimetinib Sensitive: C3 – Early Trials
RAS mutation RAS mutation	Colorectal Cancer CRC	RAS mutation RAS mutation	Colorectal Cancer CRC	pembrolizumab + selinexor Sensitive: C3 – Early Trials	pembrolizumab + selinexor Sensitive: C3 – Early Trials
RAS mutation RAS mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	RAS mutation RAS mutation	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	trametinib Sensitive: C3 – Early Trials	trametinib Sensitive: C3 – Early Trials
RAS mutation RAS mutation	Colorectal Cancer CRC	RAS mutation RAS mutation	Colorectal Cancer CRC	cetuximab Resistant: C3 – Early Trials	cetuximab Resistant: C3 – Early Trials
RAS mutation RAS mutation	Colorectal Cancer CRC	RAS mutation RAS mutation	Colorectal Cancer CRC	bevacizumab Resistant: C3 – Early Trials	bevacizumab Resistant: C3 – Early Trials
RAS mutation RAS mutation	Rectal Cancer Rectal Cancer	RAS mutation RAS mutation	Rectal Cancer Rectal Cancer	SOXIRI Sensitive: C3 – Early Trials	SOXIRI Sensitive: C3 – Early Trials
RAS mutation RAS mutation	Rectal Cancer Rectal Cancer	RAS mutation RAS mutation	Rectal Cancer Rectal Cancer	FOLFOXIRI Sensitive: C3 – Early Trials	FOLFOXIRI Sensitive: C3 – Early Trials
RAS mutation RAS mutation	Acute Myelogenous Leukemia AML	RAS mutation RAS mutation	Acute Myelogenous Leukemia AML	mTOR inhibitor Resistant: D – Preclinical	mTOR inhibitor Resistant: D – Preclinical

RAS mutation

Associations